Mogamulizumab
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
- Mogamulizumab
- Mogamulizumab: From Cutaneous T-Cell Lymphoma/ATL to Prostatic Urethra Urothelial Carcinoma
Mogamulizumab: From Cutaneous T-Cell Lymphoma/ATL to Prostatic Urethra Urothelial Carcinoma
One-Sentence Summary
Mogamulizumab is an anti-CCR4 monoclonal antibody; within this evidence pack it is referenced (in the rationale notes, not in a confirmed regulatory record) as approved for cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia-lymphoma (ATL). The TxGNN model predicts it may be effective for prostatic urethra urothelial carcinoma, but this is currently supported by 0 clinical trials and 0 publications — the prediction is model-score only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file in this pack (taiwan_regulatory.licenses is empty); rationale text for other candidates references Mogamulizumab’s known use in CTCL/ATL |
| Predicted New Indication | Prostatic urethra urothelial carcinoma |
| TxGNN Prediction Score | 99.44% (rank 12,947) |
| Evidence Level | L5 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the rationale notes attached to other candidate indications in this pack, Mogamulizumab is described as a monoclonal antibody targeting CCR4, which depletes CCR4⁺ regulatory T cells (Tregs) and induces antibody-dependent cellular cytotoxicity (ADCC) — a mechanism used to strengthen anti-tumor immune activity in its known indications (CTCL/ATL, T-cell malignancies).
The link to prostatic urethra urothelial carcinoma is a purely topological inference from the TxGNN knowledge graph, grounded in similarity between “urothelial carcinoma-type” tumors and diseases characterized by immune checkpoint/Treg exhaustion signatures — not in any direct biological or clinical evidence. Urothelial carcinoma of the prostatic urethra is mechanistically distinct from the T-cell lymphomas Mogamulizumab currently targets, and no trial, case report, or preclinical study in this pack bridges that gap.
Because original_indications is empty and original_moa is a data gap, a rigorous mechanism-to-mechanism comparison cannot be completed. This prediction should be read as a hypothesis-generating signal only, not as evidence of biological plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No marketing authorization records are currently available — taiwan_regulatory.market_status is “未上市” (Not Marketed) with 0 total licenses on file.
Cytotoxicity
Mogamulizumab is an antineoplastic monoclonal antibody (indicated per the pack’s rationale notes for CTCL/ATL, both malignancies), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-CCR4 monoclonal antibody, ADCC-mediated Treg depletion) — not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction sits at evidence level L5 (model prediction only) with zero supporting trials or literature across all queried sources (ClinicalTrials.gov, ICTRP, PubMed). A Blocking-severity data gap (DG001 — TFDA label warnings/contraindications) also prevents this candidate from entering the S1 safety pre-screen.
To proceed, the following is needed:
- TFDA/FDA label data (warnings, contraindications) to clear the Blocking data gap (DG001)
- Confirmed mechanism of action and original indication record for Mogamulizumab (DG002)
- Any preclinical or case-level evidence linking CCR4/Treg-targeted therapy to prostatic urethra urothelial carcinoma before further investment
- Note: 6 additional TxGNN-predicted indications in this pack (kidney pelvis sarcomatoid transitional cell carcinoma, infiltrating bladder urothelial carcinoma sarcomatoid variant, renal pelvis papillary urothelial carcinoma, HHV-8-related tumor, ectomesenchymoma, malignant cutaneous granular cell skin tumor) carry the same L5/Hold status and the same evidence gaps
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.